Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2021-05, Vol.22 (3), p.e442-e445
Main Authors: Kander, Elizabeth M., Shah, Manisha H., Zhou, Ye, Goyal, Ashima, Palmer, Joshua D., Owen, Dwight H., Shilo, Konstantin, Patel, Gopal, Raval, Raju R., Gonzalez, Javier, Nguyen, Michele, Olek, Elizabeth, Kherani, Jennifer, Rothenberg, S. Michael, Konda, Bhavana
Format: Article
Language:English
Subjects:
Atypical lung carcinoid
Carcinoid Tumor - drug therapy
Carcinoid Tumor - pathology
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Middle Aged
Neuroendocrine tumor
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins c-ret - antagonists & inhibitors
Pyrazoles - pharmacology
Pyrazoles - therapeutic use
Pyridines - pharmacology
Pyridines - therapeutic use
RET
RET fusion
Targeted therapeutics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2020.06.011